The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy : Data from the International Robotic Cystectomy Consortium
Copyright © 2024. Published by Elsevier Inc..
OBJECTIVE: To assess the role of neoadjuvant chemotherapy (NAC) before robot-assisted radical cystectomy (RARC) for patients with variant histology (VH) muscle-invasive bladder cancer (MIBC).
METHODS: Retrospective review of 988 patients who underwent RARC (2004-2023) for MIBC. Primary outcomes included the utilization of NAC among this cohort of patients, frequency of downstaging, and discordance between preoperative and final pathology in terms of the presence of VH. Secondary outcomes included disease-specific (DSS), recurrence-free (RFS), and overall survival (OS).
RESULTS: A total of 349 (35%) had VH on transurethral resection or at RARC. The 4 most common VH subgroups were squamous (n = 94), adenocarcinoma (n = 64), micropapillary (n = 34), and sarcomatoid (n = 21). There was no difference in OS (log-rank: P = 0.43 for adenocarcinoma, P = 0.12 for micropapillary, P = 0.55 for sarcomatoid, P = 0.29 for squamous), RFS (log-rank: P = 0.25 for adenocarcinoma, P = 0.35 for micropapillary, P = 0.83 for sarcomatoid, P = 0.79 for squamous), or DSS (log-rank P = 0.91 for adenocarcinoma, P = 0.15 for micropapillary, 0.28 for sarcomatoid, P = 0.92 for squamous) among any of the VH based on receipt of NAC. Patients with squamous histology who received NAC were more likely to be downstaged on final pathology compared to those who did not (P < 0.01).
CONCLUSION: Our data showed no significant difference in OS, RFS, or DSS for patients with VH MIBC cancer who received NAC before RARC. Patients with the squamous variant who received NAC had more pathologic downstaging compared to those who did not. The role of NAC among patients with VH is yet to be defined. Results were limited by small number in each individual group and lack of exact proportion of VH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Urologic oncology - 42(2024), 4 vom: 26. Apr., Seite 117.e17-117.e25 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cooke, Ian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Compliance |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 11.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.urolonc.2024.01.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369190017 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369190017 | ||
| 003 | DE-627 | ||
| 005 | 20240411232408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urolonc.2024.01.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM369190017 | ||
| 035 | |a (NLM)38429124 | ||
| 035 | |a (PII)S1078-1439(24)00002-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cooke, Ian |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy |b Data from the International Robotic Cystectomy Consortium |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a OBJECTIVE: To assess the role of neoadjuvant chemotherapy (NAC) before robot-assisted radical cystectomy (RARC) for patients with variant histology (VH) muscle-invasive bladder cancer (MIBC) | ||
| 520 | |a METHODS: Retrospective review of 988 patients who underwent RARC (2004-2023) for MIBC. Primary outcomes included the utilization of NAC among this cohort of patients, frequency of downstaging, and discordance between preoperative and final pathology in terms of the presence of VH. Secondary outcomes included disease-specific (DSS), recurrence-free (RFS), and overall survival (OS) | ||
| 520 | |a RESULTS: A total of 349 (35%) had VH on transurethral resection or at RARC. The 4 most common VH subgroups were squamous (n = 94), adenocarcinoma (n = 64), micropapillary (n = 34), and sarcomatoid (n = 21). There was no difference in OS (log-rank: P = 0.43 for adenocarcinoma, P = 0.12 for micropapillary, P = 0.55 for sarcomatoid, P = 0.29 for squamous), RFS (log-rank: P = 0.25 for adenocarcinoma, P = 0.35 for micropapillary, P = 0.83 for sarcomatoid, P = 0.79 for squamous), or DSS (log-rank P = 0.91 for adenocarcinoma, P = 0.15 for micropapillary, 0.28 for sarcomatoid, P = 0.92 for squamous) among any of the VH based on receipt of NAC. Patients with squamous histology who received NAC were more likely to be downstaged on final pathology compared to those who did not (P < 0.01) | ||
| 520 | |a CONCLUSION: Our data showed no significant difference in OS, RFS, or DSS for patients with VH MIBC cancer who received NAC before RARC. Patients with the squamous variant who received NAC had more pathologic downstaging compared to those who did not. The role of NAC among patients with VH is yet to be defined. Results were limited by small number in each individual group and lack of exact proportion of VH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Compliance | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Multidisciplinary | |
| 650 | 4 | |a Prostate Cancer | |
| 700 | 1 | |a Abou Heidar, Nassib |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmood, Abdul Wasay |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Jing, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Stöckle, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Andrew A |e verfasserin |4 aut | |
| 700 | 1 | |a Roupret, Morgan |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Vasdev, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Balbay, Derya |e verfasserin |4 aut | |
| 700 | 1 | |a Rha, Koon Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Aboumohamed, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Dasgupta, Prokar |e verfasserin |4 aut | |
| 700 | 1 | |a Maatman, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Richstone, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Wiklund, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Gaboardi, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Hussein, Ahmed A |e verfasserin |4 aut | |
| 700 | 1 | |a Guru, Khurshid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologic oncology |d 1995 |g 42(2024), 4 vom: 26. Apr., Seite 117.e17-117.e25 |w (DE-627)NLM097435058 |x 1873-2496 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:4 |g day:26 |g month:04 |g pages:117.e17-117.e25 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.urolonc.2024.01.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 4 |b 26 |c 04 |h 117.e17-117.e25 | ||